GeneCast Biotechnology

About

GeneCast Biotechnology is dedicated to improving cancer treatment through precision cancer diagnostics and companion diagnostics.

Beijing,Beijing,China
251 - 500

Highlights

Details

Last Funding Type: Series D
Last Funding Money Raised: ¥300M
Industries: Biotechnology,Health Care,Health Diagnostics,Medical
Founded date: Nov 1, 2014
Number Of Employee: 251 - 500
Operating Status: Active
Legal Name: GeneCast Biotechnology Co., Ltd
Also Known As: 臻和,臻和(北京)科技有限公司,Zhenhe

Genecast offers DNA testing of tumors and gene-based medicine guidance. The company claims expertise in lung, colon, liver and breast cancers. Genecast plans to use the proceeds for further research and clinical trials, as well as expanding distribution channels.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

¥300M $51M

GeneCast Biotechnology has raised a total of ¥300M $51M in funding over 2 rounds. Their latest funding was raised on Oct 26, 2020 from a Series E round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Oct 26, 2020	Series E	—	7	China Structural Reform Fund	—	Detail
Oct 30, 2019	Series D	¥300M	4	CICC	—	Detail
Feb 27, 2018	Series C	$33M	4	Loyal Valley Capital Matrix Partners China	—	Detail
Sep 18, 2017	Seed	—	1	—	—	Detail
Feb 10, 2017	Series B	$18M	1	Tsinghua Holdings	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

13

GeneCast Biotechnology is funded by 13 investors. China Structural Reform Fund and CICC are the most recent investors.

Investor Name	Lead Investor	Funding Round
China Structural Reform Fund	Yes	Series E
CICC	Yes	Series D
Loyal Valley Capital	Yes	Series C
Tsinghua Holdings	Yes	Series B
China Capital Investment Group	—	Series E
China Renaissance	—	Series E
Hillhouse Capital Group	—	Series E
Jianxin Capital	—	Series E
Matrix Partners China	—	Series E
Taikang Asset	—	Series E